Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Interpreting measures of treatment effect in cancer clinical trials.

Publication ,  Journal Article
Case, LD; Kimmick, G; Paskett, ED; Lohman, K; Tucker, R
Published in: Oncologist
2002

The efficacy of a new cancer regimen is usually assessed by analyzing outcomes such as tumor response and overall survival. Many publications summarizing results of cancer clinical trials report measures such as odds ratios and hazard ratios, as these are the estimators of treatment effect obtained from regression models used to analyze the data. However, these measures are sometimes misinterpreted, as they are not necessarily familiar to many readers. The most common mistake is to interpret both measures as relative risks, an interpretation that can lead to an incorrect impression of the impact of the treatment on response and survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncologist

DOI

ISSN

1083-7159

Publication Date

2002

Volume

7

Issue

3

Start / End Page

181 / 187

Location

England

Related Subject Headings

  • Survival Analysis
  • Risk Assessment
  • Oncology & Carcinogenesis
  • Odds Ratio
  • Neoplasms
  • Humans
  • Endpoint Determination
  • Disease Progression
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Case, L. D., Kimmick, G., Paskett, E. D., Lohman, K., & Tucker, R. (2002). Interpreting measures of treatment effect in cancer clinical trials. Oncologist, 7(3), 181–187. https://doi.org/10.1634/theoncologist.7-3-181
Case, L Douglas, Gretchen Kimmick, Electra D. Paskett, Kurt Lohman, and Robert Tucker. “Interpreting measures of treatment effect in cancer clinical trials.Oncologist 7, no. 3 (2002): 181–87. https://doi.org/10.1634/theoncologist.7-3-181.
Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002;7(3):181–7.
Case, L. Douglas, et al. “Interpreting measures of treatment effect in cancer clinical trials.Oncologist, vol. 7, no. 3, 2002, pp. 181–87. Pubmed, doi:10.1634/theoncologist.7-3-181.
Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002;7(3):181–187.

Published In

Oncologist

DOI

ISSN

1083-7159

Publication Date

2002

Volume

7

Issue

3

Start / End Page

181 / 187

Location

England

Related Subject Headings

  • Survival Analysis
  • Risk Assessment
  • Oncology & Carcinogenesis
  • Odds Ratio
  • Neoplasms
  • Humans
  • Endpoint Determination
  • Disease Progression
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis